Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Change in Account Payables (2023 - 2025)

Historic Change in Account Payables for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to $8.9 million.

  • Monte Rosa Therapeutics' Change in Account Payables rose 47310.92% to $8.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.2 million, marking a year-over-year increase of 89285.71%. This contributed to the annual value of $6.3 million for FY2024, which is 857.94% up from last year.
  • As of Q3 2025, Monte Rosa Therapeutics' Change in Account Payables stood at $8.9 million, which was up 47310.92% from -$1.1 million recorded in Q2 2025.
  • Monte Rosa Therapeutics' 5-year Change in Account Payables high stood at $13.3 million for Q4 2024, and its period low was -$10.9 million during Q1 2025.
  • For the 3-year period, Monte Rosa Therapeutics' Change in Account Payables averaged around $810363.6, with its median value being $306000.0 (2023).
  • Its Change in Account Payables has fluctuated over the past 5 years, first tumbled by 175686.27% in 2024, then surged by 47310.92% in 2025.
  • Quarter analysis of 3 years shows Monte Rosa Therapeutics' Change in Account Payables stood at $5.8 million in 2023, then skyrocketed by 130.72% to $13.3 million in 2024, then crashed by 33.27% to $8.9 million in 2025.
  • Its Change in Account Payables stands at $8.9 million for Q3 2025, versus -$1.1 million for Q2 2025 and -$10.9 million for Q1 2025.